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Thymocyte development 
in the absence of matrix 
metalloproteinase-9/gelatinase B
Natalia V. Gounko1,2, Erik Martens1, Ghislain Opdenakker1 & Vasily Rybakin1
Matrix metalloproteinases (MMP) play critical roles in a variety of immune reactions by facilitating cell 
migration, and affect cell communication by processing both cytokines and cell surface receptors. Based 
on published data indicating that MMP-9 is upregulated upon T cell activation and also in the thymus 
upon the induction of negative selection, we investigated the contribution of MMP-9 into mouse T cell 
development and differentiation in the thymus. Our data suggest that MMP-9 deficiency does not result 
in major abnormalities in the development of any conventionally selected or agonist selected subsets 
and does not interfere with thymocyte apoptosis and clearance, and that MMP-9 expression is not 
induced in immature T cells at any stage of their thymic development.
Gelatinase B/matrix metalloproteinase-9 (MMP-9) is a calcium-dependent, zinc-containing endopeptidase 
involved into the remodeling of extracellular matrix in a wide variety of biological phenomena, and an increasing 
body of evidence suggests that it plays an important role in the regulation of multiple immune processes1,2. It 
has been well documented that processing of extracellular matrix by MMP-9 is crucial for movement through 
and invasion into tissues by multiple cell types, including cancer cells, neutrophils, macrophages, dendritic and 
T cells3–10. MMP-9-mediated cleavage has also been shown to regulate the activity of a number of cytokines 
and chemokines11–16. MMP-9-deficient mice display elevated levels of autoantibodies to a variety of antigens17. 
A growing body of evidence also indicates that MMP-9 may play a more direct role in the regulation of T cell 
activation, although the data remain highly fragmented. Cleavage of ICAM-1 by MMP-9 protects cultured breast 
cancer cells from NK cell-mediated cytotoxicity18. It is likely that the same mechanism may also provide immu-
nosuppressive input in both conventional and regulatory T cell-mediated responses since LFA-1 interaction with 
ICAM-1 is crucial for immune synapse stabilization and T cell activation19. Indeed, MMP-9 deficiency results in 
reduced recruitment of T cells and macrophages and attenuated pathology in experimental glomerulonephritis5. 
Another possible role for MMP-9 arises from the observation that MMP-9 produced by cancer cells cleaves CD25 
expressed on the surface of tumor-infiltrating T cells and reduces their proliferation in vitro20, suggesting that 
a similar mechanism may downregulate T cell activation in vivo by limiting T cell reactivity to IL-2. Chemical 
inhibition of MMP-9 reduces proliferation of regulatory T cells in the presence of CD3/CD28-coated microbeads 
in vitro, although puzzlingly so does the addition of recombinant MMP-9 in the same study21. Finally, both 
human and mouse T cells and T cell lines have been shown to express and secrete active MMP-9 in response 
to antigenic stimulation22–24, upon chemical stimulation25–28, in response to tumors29, and downstream of cell 
adhesion-related signals30,31, although the regulation and biological significance of T cell intrinsic production of 
MMP-9 remain poorly understood. In addition, purity analysis of MMP-9-producing cell populations has not 
been fully reported in multiple studies.
Direct attempts to evaluate the involvement of MMP-9 into T cell activation by comparing MMP-9-sufficient 
and -deficient peripheral T cell responses have yielded conflicting data. Using mixed lymphocyte reaction assays, 
two studies from the same group reported an increased proliferation of MMP-9-deficient T cells upon stimula-
tion with Balb/c dendritic cells, and increased production of IL-12 and IFNγ 32,33. Intriguingly, the authors also 
observed increased proliferation of wild-type T cells derived from mice stimulated by MMP-9-deficient den-
dritic cells in mixed lymphocyte reaction, as compared to stimulation with wild-type DC. These data appear to 
suggest that MMP-9 activity suppresses T cell activation regardless of cell type of origin. In agreement with this 
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conclusion, addition of recombinant MMP-9 to effector T cells stimulated with CD3/CD28-coated beads strongly 
suppressed their proliferation21. However, a later study has revealed a dramatic decrease in the proliferation of 
MMP-9 knockout T cells as well as in IL-2 and CD25 production in response to stimulation with anti-CD3 anti-
body23. The reasons behind these discrepancies remain to be experimentally addressed.
Odaka and colleagues (2005) reported a transient increase in the expression of MMP-9 in thymic tissue of 
Balb/c mice 16–24 hours after a single i.p. injection of CD3ε antibody mimicking negative selection34. Elevated 
MMP-9 production coincided with the exposure of cryptic epitopes of collagen IV as revealed by HUIV26 anti-
body staining, and with increased neovascularization of the thymus34. In a separate study, application of the 
broad spectrum MMP inhibitor GM6001 was shown to delay TCR rearrangement, inhibit the proliferation and 
progression of thymocytes from CD4−CD8− (double negative, DN) to CD4+CD8+ (double positive, DP) stage in 
ex vivo thymocyte development assays35. Finally, our own data indicated that MMP-9 deficiency combined with 
lpr mutation in the Fas gene resulted in thymic hyperplasia17. Based on these data, we decided to systematically 
analyze the requirement for MMP-9 during thymic T cell development, and induction of MMP-9 expression in 
developing thymocytes in response to stimulation.
Materials and Methods
Mice. Experimental protocols were approved by the Ethische Commissie Dierproeven, KU Leuven, animal 
protocol number B277-2014, laboratory license LA1210251 (Belgium). Animal use was in accordance with insti-
tutional permits and KU Leuven ethics policies. MMP-9-deficient mice and MMP-9−/−FasLpr mice were described 
previously17. Here, we used MMP-9−/− after 13 backcrosses into the C57BL/6J strain. MMP-9-sufficient C57BL/6J 
and FasLpr control mice were bred and housed in the same vivarium under exactly the same environmental con-
ditions for several years. Photographic images were taken using a Canon EOS3200 camera equipped with a stabi-
lized objective Canon EFS 18–55.
Antibodies, flow cytometry, and immunohistochemistry. The following antibodies were used for 
flow cytometry: CD4 (GK1.5), CD5 (53–7.3), CD8β (H35-17.2), CD25 (7D4), CD44 (IM7), F4/80 (BM8), Gr.1 
(1A8-Ly6g), TCRβ (H57-597), γ δ TCR (GL-3), all at 2 μ g/ml, and Foxp3 (FJK-16s) at 5 μ g/ml, all from either 
eBioscience or BD Biosciences. Goat polyclonal antibody against MMP-9 antibody used in flow cytometry 
(2 μ g/ml) and immunohistochemistry experiments (2 μ g/ml) was from R&D Systems (cat. # AF909). Intracellular 
staining for MMP-9 was performed using Intracellular Fixation and Permeabilization Buffer Set (eBioscience) 
and anti-goat secondary antibody labeled with AlexaFluor 647, used at 0.5 μ g/ml (ThermoFisher Scientific). Data 
were acquired on BD LSR Fortessa X-20 flow cytometer and analyzed using FlowJo software, version 7.6.5. Iba1 
antibody used for immunohistochemistry was from Wako, used 1:200 (cat. # 019-19741). Immunohistochemical 
stainings were carried out on a Ventana Ultra staining platform according to manufacturer’s instructions (Roche).
Thymocyte apoptosis and deletion assays. For in vivo induction of thymocyte deletion, three to four 
4–5 week old mice per genotype were injected i.p. with 50 μ g of anti-CD3ε antibody (clone 145-2C11, puri-
fied, sodium azide-free, low endotoxin, BD Biosciences) in 200 μ l of sterile PBS, and one sex- and age-matched 
mouse was injected with 200 μ l of sterile PBS. Mice were sacrificed 18 or 72 h post injection. In total, 13–14 
CD3ε -injected and 4 PBS-injected mice were used per genotype in four independent injection experiments. 
For in vitro induction of apoptosis, thymi were isolated from 4–5 week old mice, and thymocytes were isolated 
by pressing the tissue through 70 μ m cell strainers (BD). Cells were counted and incubated at 37 °C in 96-well, 
flat-bottom plates in the presence of CD3/CD28-coated magnetic beads (ThermoFisher Scientific). Cells were 
harvested after 18 h and analyzed for activation of caspase 3 using CaspGLOW Fluorescein Active Caspase-3 
Staining Kit (FITC-VAD-FMK, eBioscience) and for surface expression of Annexin V using Annexin V Apoptosis 
Detection Kit (eBioscience). Analysis of apoptosis by flow cytometry was performed as described36,37.
Electron microscopy. For morphological analysis, thymi were fixed in 2.5% glutaraldehyde, 4% formalde-
hyde, 0.2% picric acid, in 0.1 M sodium cacodylate buffer (pH 7.4) and stored in the same fixative at 4 °C. Samples 
were embedded in 3% agarose and sectioned at 150 μ m using a vibratome. Sections were postfixed in 1% osmium 
tetroxide, 1.5% potassium ferrocyanide for 30 min at room temperature, stained with 0.2% tannic acid for 20 min, 
fixed with 1% osmium tetroxide for 30 min, stained with 1% thiocarbohydrazide for 20 min, and incubated again 
with 1% osmium tetroxide for 30 min. Samples were contrasted with 0.5% uranyl acetate in 25% methanol over-
night at 4 °C and with Walton’s lead acetate for 30 min at 60 °C. After ethanol dehydration, samples were infiltrated 
and embedded into Agar 100. Blocks were sectioned at 110 nm using a Leica UCT ultra-microtome, collected 
onto Cu-grids coated with formvar/carbon, and imaged using JEOL JEM1400 transmission electron microscope 
operated at 80 kV and equipped with an 11-MP Olympus Quemesa camera.
For immunoelectron microscopy, thymi were fixed in 4% formaldehyde in 0.1 M sodium cacodylate buffer 
(pH 7.4) and stored in the same fixative at 4 °C. Samples were embedded in 3% agarose, sectioned at 150 μ m using 
a vibratome, and small discs were punched out of the sections for freeze-substitution in a Leica AFS2 apparatus. 
The starting point was at 0 °C in 30% ethanol for 30 min, then lowered to − 15 °C to − 30 °C in 50% ethanol for 
30 min, − 30 °C to − 35 °C in 75% ethanol for 30 min, and at − 35 °C ethanol was replaced with acetone for 1 h. 
Samples were stained with 0.2% uranyl acetate in acetone for 4 h, washed 3x in acetone, and infiltrated with lowic-
ryl HM20 at − 35 °C for 48 h. UV polymerization was initiated for 24 h at − 35 °C, then temperature was raised 
to 20 °C at a rate of 1 degree/h, together with UV polymerization. Blocks were sectioned at 110 nm using a Leica 
UCT ultra-microtome, and sections were collected on Ni-grids coated with formvar/carbon. Immunostaining 
was performed as described38. Anti-MMP-9 antibody AF909 was used at 1:30, and anti-goat immunoglobulins 
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coupled to 10-nm gold particles (EMS) were used at 1:100. Sections were counterstained with uranyl acetate and 
lead citrate and imaged as above.
Zymography. Frozen thymi were thawed on ice, homogenized, lysed, purified by gelatin-Sepharose affin-
ity chromatography, separated by gel electrophoresis, and analyzed by gelatin zymography as described previ-
ously39,40. As an internal control (IC), a known amount of recombinant human proMMP-9Δ OGHem (MMP-9 
deletion mutant lacking hemopexin and O-glycosylation domains) was added to each sample. For the analysis 
of MMP-9 production in ex vivo stimulated cells, stimulations were carried out in serum-free synthetic medium 
(TexMACS, Miltenyi Biotec) for indicated periods of time, and supernatants were frozen at − 80 °C. Thawed 
samples were purified and analyzed as above. Band densitometry was performed using ImageJ ver. 1.51a mod-
ules “Plot Lanes” and “Wand/Tracing Tool” in photographic images of Coomassie Blue-stained zymography gels 
rotated 0–5° to produce near-vertical bands and cropped to the shown area. No other image manipulations such 
as brightness or contrast adjustments were performed.
Results
Thymic T cell development in the absence of MMP-9. In agreement with published data, MMP-9 
deficiency alone did not result in any obvious abnormalities in thymic size and gross morphology (refs. 17,34 and 
Fig. 1a–c), although there was an approx. 10% increase in thymic cellularity (Fig. 1d).
Figure 1. Thymic morphology, cellularity and frequency of major cell subsets. (a) Gross anatomy of thymi 
in wild-type (top) and MMP-9-deficient (bottom) mice. Photographic images show two 4-week old mice per 
genotype, dissected to expose the thymi. Representative of ten animals per genotype. (b) Thymus size and gross 
morphology in wild-type and MMP-9-deficient mice. Organs from three individual animals per genotype were 
extracted and photographed. Representative of ten animals per genotype. (c) Thymus weight in wild-type and 
MMP-9-deficient mice. Organs from ten individual animals per genotype were weighed immediately following 
extraction. p-value results from a two-tailed Mann-Whitney U-test. (d) Overall cellularity is slightly increased 
in MMP-9 deficient mice. Thymi were isolated and pressed through 70 um mesh into PBS. Cell counting was 
done in three replicates per thymus, and average counts plotted. Data indicative of twelve mice per genotype. 
p-value results from a two-tailed Mann-Whitney U-test. (e) Phenotype of early T cell precursors. Flow 
cytometry plots represent the distribution of double negative, lineage-negative (CD3, Ly-6G/Ly-6C, CD11b, 
CD45R, TER-119) thymocytes based on surface CD44 and CD25 staining. Data representative of eight mice 
per group in two independent experiments. (f) Major thymocyte subsets. Flow cytometry plots represent the 
distribution of all live, single thymocytes based on surface CD4 and CD8 staining. Data representative of twelve 
mice per group in three independent experiments.
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The percentage and composition of immature, CD4/CD8-double negative thymocytes were indistinguisha-
ble between MMP-9-sufficient and -deficient mice (Fig. 1e). Proportions of double-positive and single-positive 
lymphocytes were also identical (Fig. 1f), suggesting an absence of defects in either positive or negative selection. 
Next, we analyzed the abundance of rare thymocyte populations surviving strong selecting signals and giving 
rise to agonist-selected subsets. Regulatory T cell precursors were detected within the CD4 single positive pop-
ulation with the use of Foxp3 and CD25 staining (Fig. 2a), and γ δ T cell precursors were detected within CD4/
CD8-double negative subset by direct staining with a γ δ TCR antibody (Fig. 2b). The thymocyte subset containing 
precursors of intraepithelial CD8α α lymphocytes was revealed using TCRα β and CD5 antibody staining and 
enumerated within the double negative subset as described41 (Fig. 2c). Percentages of precursors of γ δ T cells and 
intraepithelial CD8α α cells were identical, whereas precursors of regulatory T cells displayed a minor (< 10%) but 
reproducible decrease in MMP-9 knockout thymi (Fig. 2d).
In order to test the potential input of MMP-9 into thymocyte apoptosis and clearance during negative selec-
tion, we tested the effects of CD3ε antibody treatment in vivo and in vitro. Incubation of thymocytes with mag-
netic beads coated with antibodies against CD3 and CD28 resulted in massive apoptosis, as indicated by annexin 
V-positive and activated caspase 3-positive staining (Fig. 3A). The onset and magnitude of cell death were indis-
tinguishable between MMP-9-sufficient and -deficient samples, indicating that MMP-9 is not required for thymo-
cyte apoptosis in response to strong stimulation. Because MMP-9 function has been associated with macrophage 
activity, we then analyzed the clearance of apoptotic thymocytes in vivo. We injected MMP-9-sufficient and 
-deficient mice i.p. with anti-CD3ε antibody as described in Materials and Methods, and analyzed thymic deletion 
after 48 hours. In both cohorts, double-positive thymocytes were effectively cleared, indicating the lack of require-
ment for MMP-9 activity (Fig. 3b,c). Dulling of surface coreceptors occurred efficiently in both cohorts (data not 
shown). In light of our previous data indicating a potential synergy between MMP-9 and Fas in the thymus17, 
we also analyzed thymocyte deletion in mice in which the Fas mutation lpr was present. In these animals, thy-
mocyte deletion was also unaffected by MMP-9 deficiency (Fig. 3b,c). In all cohorts, CD3ε antibody injection 
Figure 2. Frequencies of agonist selected thymocytes. (a) Thymic precursors of regulatory T cells. Flow 
cytometry plots represent the distribution of CD4 single-positive thymocytes based on surface CD25 and 
intracellular Foxp3 staining. Data representative of twelve mice per group in two independent experiments.  
(b) Thymic precursors of γ δ T cells. Flow cytometry plots represent the distribution of double negative 
thymocytes based on surface γ δ TCR and TCRβ staining. Data representative of twelve mice per group in two 
independent experiments. (c) Thymic precursors of CD8α α intraepithelial lymphocytes. Flow cytometry plots 
represent the distribution of double-negative, NK1.1- and B220-negative thymocytes based on surface CD5 and 
TCRβ staining. Data representative of twelve mice per group in two independent experiments. (d) Statistical 
analysis of agonist selected T cell frequencies in the thymus. All significance labels and p-values are derived 
from two-tailed Mann-Whitney U-tests.
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led to a transient weight loss and stress behaviors which are known to be caused by systemic cytokine storm and 
dehydration. Percentage of weight loss was similar between all genotypes (Fig. 3d).
Morphological analysis of thymocyte apoptosis upon in vivo application of CD3ε antibody did not reveal any 
differences between MMP-9-sufficient and -deficient mice. Ultrastructural analysis revealed a massive increase 
in apoptotic events, as indicated by highly compact, dark, and deformed nuclei, degradation of cell membranes, 
and autophagy events in the cytoplasm (Fig. 4). Thymocyte phagocytosis events were rare but present in both 
genotypes (Fig. 4). 
Expression of MMP-9 in the thymus. Because earlier works detected the presence of MMP-9 in thymic 
tissue, we were interested in identifying cell populations responsible for its expression, particularly among T cell 
subsets. We confirmed the upregulation and activation of MMP-9 in the thymus following i.p. CD3ε antibody 
injection (Fig. 5a). It is noteworthy that the upregulation of MMP-9 after stimulation coincided with a reduction 
of MMP-2 signal, which occurred in both MMP-9-sufficient MMP-9-deficient tissue. A drop in MMP-2 may 
reflect its active downregulation upon stimulation, or may be indicative of a decrease in the abundance of pro-
ducing cells. Critically, isolated thymocytes stimulated with CD3/CD28 beads did not produce MMP-9 after 4 h 
in vitro (Fig. 5b). No upregulation was detected after 1, 2, or 18 h in vitro stimulation (not shown). Furthermore, 
MMP-2 signal remained unchanged after in vitro stimulation, suggesting that the effect observed in the total 
Figure 3. Analysis of negative selection. (a) In vitro analysis of thymocyte apoptosis. Isolated thymocytes 
were incubated in vitro in complete RPMI in the absence or presence of CD3/CD28-coated magnetic beads, 
added at 1:1 ratio. Flow cytometry plots represent the distribution of all single thymocytes based on surface 
annexin V and intracellular active caspase 3 staining. Data representative of four technical replicates per group 
in four independent experiments (16 wells per group total). (b) In vivo analysis of thymocyte deletion. Mice 
were injected with PBS or CD3ε antibody as described in Materials and Methods. Thymi were excised 48 h post 
injection. Flow cytometry plots represent the distribution of all single thymocytes based on surface CD4 and 
CD8α staining. Data representative of 13–14 CD3ε -injected mice per group and four PBS injected mice per 
group in four independent experiments. (c) Statistical analysis of double positive thymocyte frequencies in the 
thymus. All significance labels and p-values are derived from pairwise, two-tailed Mann-Whitney U-tests.  
(d) Body weight loss after CD3ε antibody injection. Four mice per genotype were injected i.p. with CD3ε 
antibody, and their body weight was recorded over four days in 24-hour intervals. p-values are derived from 
grouped Kruskal–Wallis one-way analysis of variance between CD3ε -injected WT, MMP9 KO, and FasLpr 
MMP9 KO mice, at each time point. Gray symbols indicate PBS-injected mice (one per genotype, as in c). 
Representative of two independent experiments.
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thymus (Fig. 5a) is most likely attributable to cells of non-T lineage. Immunohistochemical analysis revealed 
strong and specific MMP-9 reactivity associated with a small number of round cells enriched in the thymic cortex, 
and specifically excluded from Iba1-positive cells of dendritic morphology which include cortical and medullar 
stromal cells and macrophages42 (Fig. 5c). In mice injected with CD3ε antibody, MMP-9 displayed a similar dis-
tribution pattern although the number of MMP-9-positive cells was increased (Fig. 5c). MMP-9-deficient tissue 
exhibited non-specific staining of cells attached to the outside of the thymic capsule, and weak diffuse staining of 
the capsule-proximal cortex, but not of any intrathymic cells (Fig. 5d).
In order to identify the MMP-9-positive cells, we first validated a commercial polyclonal anti-MMP-9 anti-
body (see Materials and Methods) for intracellular staining combined with flow cytometry. The antibody strongly 
stained Gr.1high cells in bone marrow (Fig. 6a) and lymph nodes (data not shown) of wild type mice. In the thymus, 
the immunoreactivity was exclusively present in a small population of Gr.1high, CD4/CD8 double-negative cells 
corresponding to either thymus-resident neutrophils or neutrophils confined within intrathymic blood vessels43  
(Fig. 6b), and no immunoreactivity was associated with any T cell precursor subset including single- or 
double-positive thymocytes. These findings were further confirmed by immunoelectron microscopy which read-
ily detected MMP-9 in perivascular cells, in the lumen of thymic vessels (Fig. 7a), and in tissue-resident polymor-
phonuclear leukocytes (Fig. 7b) but did not reveal MMP-9 reactivity in apoptotic or non-apoptotic thymocytes 
from anti-CD3ε injected or non-injected mice.
Figure 4. Morphological analysis of thymocyte apoptosis in situ. Mice were injected i.p. with PBS (top panel) 
or CD3ε antibody (middle and bottom panels). Thymi were excised 48 h post injection and processed for 
electron microscopic analysis as described in Materials and Methods. Images representative of 40–50 individual 
microscopic images and two individual animals per condition. Bottom panels show engulfment of apoptotic 
thymocytes. Scale bars, as indicated.
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Discussion
Development of immature T cells in the thymus involves a series of stimulatory interactions with thymus-resident 
cells which are necessary for the survival, proliferation, and selection of T cells and ultimately for the formation of 
a functional T-cell repertoire44. During positive selection, interactions with weak self-ligands provide tonic signals 
required for survival, and the lack of such stimuli, e.g. in immature T cells expressing dysfunctional T cell recep-
tors, results in death by neglect. Conversely, during negative selection interactions with strong self-ligands result 
in the induction of apoptosis and are required for the elimination of self-reactive clones from the mature T cell 
repertoire. Specific small subsets of immature T cells can survive strong stimulation by self-antigens in the thy-
mus, and develop into several highly specialized, “agonist-selected” cell types, such as regulatory T cells and sev-
eral others45. Changes in the cellular perception of selecting signals lead to profound developmental abnormalities 
and can result in immune deficiencies and autoimmunity. Dampening of T cell receptor signaling by the adaptor 
protein Themis and tyrosine phosphatase Shp-1 has been shown to establish the survival threshold between 
positive and negative selection, and lack of either of these molecules severely reduced thymic output due to 
increased signaling in response to weak ligands and increased negative selection37,46,47. Interference with thymo-
cyte apoptosis results in the survival of self-reactive T cell specificities and leads to autoimmune manifestations48. 
Deletion of the transcription factor Aire which is required for the expression of non-thymic antigens by thymic 
Figure 5. Identification of MMP-9 producing cells in the thymus. (a) Mice were injected i.p. with PBS or 
CD3ε antibody. Thymi were excised 20 h post injection and processed for zymography. Left, zymography 
data representative of two independent experiments with material from one mouse per condition in each 
experiment. Locations of MMP-9, MMP-2, and internal control (IC, see Materials and Methods) are indicated. 
A double arrowhead highlights the band shift characteristic of MMP-9 activation. Densitometry data reflecting 
band intensities of MMP-9 and MMP-2 relative to their internal controls were calculated using ImageJ (see 
Materials and Methods), and are indicated below. Right, changes of expression of MMP-9 and MMP-2 relative 
to wild-type PBS control, derived from densitometry analysis. (b) Isolated thymocytes were incubated  
in vitro in serum-free TexMACS medium in the absence or presence of CD3/CD28-coated magnetic beads, 
added at 1:1 ratio, for 4 h. Culture supernatants were processed for zymography. Data representative of four 
independent experiments with cells derived from one mouse per experiment. Labeling and densitometry 
as above. Right, changes of expression of MMP-9 and MMP-2 relative to untreated control sample, derived 
from densitometry analysis. (c) Mice were injected i.p. with PBS (left) or CD3ε antibody (right). Thymi were 
excised 48 h post injection, fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and processed for 
immunohistochemistry. (d) Specificity analysis of immunohistochemical staining. MMP-9 specificity control 
(left): CD3ε -injected sample from an MMP-9-deficient mouse shows non-specific staining of cells attached 
to the outside of the thymic capsule, and weak diffuse subcapsular staining, and no stained cells in the thymic 
tissue. Iba1 specificity control (right): PBS-injected sample stained using anti-rabbit secondary antibody 
without primary antibody shows negligible background staining. The highlighted area is duplicated in the inset 
after artificial enhancement of brightness and contrast to reveal biological structure.
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epithelial cells causes a restriction in the repertoire of self-antigens available for negative selection and manifests 
in a systemic autoimmune syndrome49,50.
Stimulation of developing thymocytes by systemic application of anti-CD3ε antibody mimics the extreme case 
of negative selection in TCR-polyclonal mice and results in massive induction of thymocyte death in vivo and 
in vitro51,52. Apoptotic cells in the thymic cortex closely associate with macrophages which are actively recruited to 
the thymus following stimulation by antibody53. Published data indicated an increase in MMP-9 expression in the 
thymus following CD3ε antibody injection, although specific increase in developing T cells was not reported34. 
Because developing thymocytes are the major subset responding to CD3ε stimulation in the thymus, we hypoth-
esized that these cells may upregulate MMP-9. The biological significance of such upregulation could rely on 
generation of additional peptides for selection, processing of cell surface receptors and subsequent modification 
of cellular signaling, regulation of cell contact duration, or other mechanisms.
We have previously reported that the deletion of MMP-9 in mice harboring the lpr mutation in the Fas gene 
resulted in an increase in thymus size, although it remains unknown if this effect is due to increased proliferation 
in the thymus, less efficient selection, or other mechanisms17. Fas is expressed in thymocytes54, acts in cis55, and 
is important for cell clearance in both positive and negative selection56–58, although it appears to be involved in 
the elimination of a relatively small percentage of selected thymocytes and only in response to relatively weak 
negatively selecting signals56,59–61. A separate Fas-independent, Bim-dependent mechanism has been shown 
to be activated in conjunction with negative selection62–64. Intriguingly, at least one matrix metalloproteinase, 
MMP-7/matrilysin cleaves both Fas and FasL65,66. MMP-7-mediated cleavage of Fas reduces susceptibility of 
target cells to apoptosis induced by cytotoxic T cells, Fas antibody, and chemical stimuli65–67, whereas cleavage 
of membrane-associated FasL produces a soluble fragment which is biologically active in inducing target cell 
Figure 6. Flow cytometry analysis of MMP-9 expressing populations. (a) Specificity of intracellular MMP-9 
staining. Plots represent the distribution of all single bone marrow-derived cells based on surface Gr.1 and 
intracellular MMP-9 staining. Cells were stained for Gr.1, fixed, permeabilized, and stained with MMP-9 
antibody and then secondary antibody (top and bottom panels) or secondary antibody alone (middle panel). 
MMP-9 staining exceeding background level as defined by the signal in the knockout sample was exclusively 
present in Gr.1-high cells. Data representative of four mice per genotype in two independent experiments. (b) 
Expression of MMP-9 in the thymus. Plots represent the distribution of all single thymocytes based on surface 
CD4, CD8α , Gr.1, and F4/80 staining, and intracellular MMP-9 staining. Data representative of two mice per 
experiment and two independent experiments.
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apoptosis68. Enhancement of thymus hyperplasia in FasLpr mice by MMP-9 deficiency hinted to the possibility of 
involvement of the latter into thymocyte clearance.
We have extensively tested both hypotheses by comparing thymocyte development in mice sufficient and 
deficient for MMP-9. Our data clearly suggest that thymocyte development does not require MMP-9 activity. All 
thymic subsets were represented at appropriate proportions in MMP-9-deficient mice, with an exception of a < 10% 
decrease in regulatory T cell percentage, and in vitro stimulation of thymocytes from both mouse cohorts 
revealed no differences in developmental outcomes. Perhaps more surprisingly, MMP-9 deficiency did not result 
in any abnormalities in the clearance of apoptotic thymocytes in mice both in C57BL/6 mice and FasLpr mice. A 
small increase in thymic cellularity and a small decrease in thymic regulatory T cell percentage suggest that an 
MMP-9-dependent mechanism may play an accessory role in the agonist selection of this particular subset and 
in thymocyte proliferation. One candidate molecule is TGFβ which can be released from its latent precursor form 
by MMP-9-mediated cleavage12. However, while TGFβ is central to the peripheral conversion and maintenance 
of regulatory T cells, T cell-specific deletion of Tgfbr2 gene revealed no changes in the thymic development of 
this subset or in fact any α β T cell subset, or indeed in thymic cellularity69. It is also important to notice that the 
small increase in thymic cellularity in MMP-9 knockout mice does not translate into an increase in cellularity in 
peripheral lymphoid organs17.
We further concluded that developmental signaling in the thymus does not result in detectable T cell-intrinsic 
upregulation of MMP-9 expression. While MMP-9 was readily detected in thymic neutrophils, no T cell sub-
set revealed MMP-9 reactivity in either flow cytometry or immunohistochemistry assays. In vitro stimulation 
of isolated thymocytes with CD3/CD28-coated microbeads did not result in upregulation of MMP-9 levels, as 
demonstrated in zymography experiments.
MMP-9 expression in thymic tissue and its upregulation upon CD3ε antibody injection has been described 
before, and correlated with neovascularization of the thymus34. The authors of that study hypothesized that this 
mechanism may increase the abundance of macrophages required for the clearance of apoptotic thymocytes. 
While this may indeed be the case, the functional consequences of MMP-9 dependent neovascularization and 
additional macrophage influx appear negligible as the lack thereof does not lead to any differences in thymo-
cyte elimination. While more research is needed to better understand the importance of MMP-9 for the biology 
of thymic macrophages and neutrophils, our data suggest that its role is unrelated to thymocyte development 
and differentiation. The increased abundance of MMP-9-positive cells after stimulation in vivo but not in vitro 
suggests an influx of MMP-9-expressing cells from the bloodstream rather than induction of expression in a 
thymus-resident population.
Multiple matrix metalloproteinases have been implicated in thymocyte development and homeosta-
sis. Similarly to MMP-9, stromelysins MMP-3, - 10, and - 11 are induced in thymi of mice injected with CD3ε 
Figure 7. Morphological analysis of MMP-9 expression. Thymi were excised and processed for 
immunoelectron microscopic analysis as described in Materials and Methods. Numbered areas of interest are 
enlarged in the higher magnification images on the right, and circles highlight the immunogold label. Images 
representative of 40–50 individual microscopic images and two individual animals. Scale bars, as indicated.
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antibody, and at least one of these, MMP-11 was detected in macrophages associated with apoptotic thymocytes70. 
Membrane-associated MMP-14 is upregulated in human thymocytes incubated on laminin-5 and implicated in 
the generation of soluble fragment of CD44 thought to induce migration71. MMP-19 has been shown to promote 
thymocyte proliferation specifically in young mice, where its deletion led to a partial block in DP-SP transition72. 
Activity of thymic plasmin which is known to process multiple matrix metalloproteinases including the afore-
mentioned MMP-373, MMP-1174, and MMP-1475, as well as MMP-976, is increased upon CD3ε antibody injec-
tion34. A concerted action of MMP-9 and other matrix metalloproteinase(s) such as MMP-11, -14, -19, or other 
may result in functional redundancy and mask a phenotype of a single MMP knockout. As a final remark, care 
should be taken when interpreting thymus-specific effects of CD3ε antibody injections on non-T cell subsets 
which are also highly represented in the bloodstream and peripheral lymphoid organs. Massive cytokine storm 
caused by antibody-mediated T cell activation77 is very likely to strongly affect thymic subpopulations of non-T 
cells and non-thymus resident T cells, e.g. those located within thymic blood vessels.
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